Pediatric rheumatology

Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE

Lupus Sci MedPublished Longitudinal cohort study

Authors' conclusion

Patients with LN and pre-existing damage are at higher risk of increased future damage acquisition, even if achieving a T2T state such as LLDAS. Among proposed common T2T states, the LLDAS is the hardest to achieve and maintain.

Study context

Population
Childhood-onset SLE patients in the Cincinnati Lupus Registry, followed up until 18 years of age (lupus nephritis (LN): 45, white: 95)LN: 45
Participants
165 patients
Exposure
Treat-to-target states compared: SLEDAI-LD vs low-CS vs lupus low disease activity state (LLDAS)
Outcome
Achievement of T2T states during follow-up (median 4 years)
Methodological detailsregistry-based (Cincinnati Lupus Registry)
  • Registry-based (Cincinnati Lupus Registry)

Main finding

As reported in the abstract

Patients with LN significantly less likely to achieve any treat-to-target (T2T) state
all p<0.03
Patients with LN required significantly longer time to reach T2T states
all p<0.0001

Observational data: associations, not effects.

Further findings

New damage despite reaching T2T state

Median

OutcomeSLEDAI-LDLow-CSLLDAS
Proportion of follow-up time T2T state maintained86% (IQR 55%–100%)76% (IQR 48%–100%)39% (IQR 13%–64%)
New damage despite reaching T2T state — Higher risk of new damage with LN vs without LN despite achieving low-CS
p=0.009
New damage despite reaching T2T state — Higher risk of new damage with LN vs without LN despite achieving LLDAS
p=0.04

Predictors of failure to maintain LLDAS

LN
P ≤ 0.0062
Pre-existing damage
P ≤ 0.0271
Non-white race
P ≤ 0.0013

Original publication

Usefulness of the lupus low disease activity state as a treatment target in childhood-onset SLE. Lupus Sci Med. Published 30 May 2023. doi:10.1136/lupus-2022-000884

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.